Last Updated: June 9, 2026

Suppliers and packagers for ADDERALL XR 15


✉ Email this page to a colleague

« Back to Dashboard


ADDERALL XR 15

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Takeda Pharms Usa ADDERALL XR 15 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303 NDA AUTHORIZED GENERIC Sandoz Inc 0781-2329-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0781-2329-01) 2009-04-02
Takeda Pharms Usa ADDERALL XR 15 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303 NDA AUTHORIZED GENERIC Sandoz Inc 0781-2335-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0781-2335-01) 2009-04-02
Takeda Pharms Usa ADDERALL XR 15 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303 NDA AUTHORIZED GENERIC Sandoz Inc 0781-2343-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0781-2343-01) 2009-04-02
Takeda Pharms Usa ADDERALL XR 15 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303 NDA AUTHORIZED GENERIC Sandoz Inc 0781-2352-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0781-2352-01) 2009-04-02
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for ADDERALL XR 15

Last updated: April 25, 2026

Who Supplies Adderall XR 15 (amphetamine mixed salts extended-release)?

No complete, defensible supplier map can be produced from the available inputs. Under patent- and product-grade diligence standards, “supplier” can mean (1) the marketing authorization holder, (2) finished-dose manufacturer, (3) active pharmaceutical ingredient (API) suppliers, (4) excipient/packaging suppliers, or (5) contract manufacturing organizations (CMOs) and labeled-manufacturer sites. Without these definitions and without product-manufacturer disclosure evidence tied specifically to Adderall XR 15 mg (NDC-specific labeling), any list would be non-actionable.

What is knowable from public product labeling at this level?

For Adderall XR 15 mg, supplier identification that is suitable for R&D or investment decisions must be anchored to one of the following primary documents:

  • U.S. FDA “Prescription Drug Labeling” that names the manufacturer, packager, and distributor on the container label and package insert
  • FDA Orange Book entries that link the product to listed manufacturers (company and dosage-form specific)
  • Approved application references (e.g., NDA holder) that identify the applicant/holder versus manufacturing site
  • Current Good Manufacturing Practice (cGMP) inspection and establishment lists tied to the named manufacturing sites

Without those primary citations for the 15 mg strength, no compliant supplier list can be delivered.

Key Takeaways

  • “Supplier” for Adderall XR 15 mg must be specified (NDA holder, finished-dose manufacturer, API supplier, or CMO site).
  • A defensible supplier list requires strength- and NDC-specific labeling or Orange Book/manufacturer entries.
  • Presently, the inputs do not support a complete and accurate supplier mapping for Adderall XR 15.

FAQs

1) Is the NDA holder the same as the manufacturer for Adderall XR 15 mg?
Not necessarily. NDA holders and labeled manufacturers often differ. The difference depends on the product labeling and the Orange Book listing for the specific dosage form.

2) Can API suppliers be identified reliably from generic public sources?
No. API sourcing is frequently disclosed only through regulatory listings, DMF references, inspections, or company disclosures tied to specific strengths and suppliers.

3) Do contract manufacturers change over time for Adderall XR?
Yes. cGMP sites and CMOs can change with supplements, manufacturing transfers, and packaging changes.

4) Should supplier diligence be done by NDC and strength rather than product name?
Yes. Strength-level formulation and labeling can correspond to different packaging configurations and sometimes different manufacturing sites.

5) What is the highest-evidence document to list “suppliers” for a branded solid oral product?
The package insert/container labeling manufacturer section and the FDA Orange Book entry for the specific strength and dosage form.

References

(No sources were provided in the prompt, and no claimable product-manufacturer or Orange Book evidence can be cited.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.